 SAN DIEGO, Sept. 27, 2021 GLOBE NEWSWIRE -- Otonomy, Inc. Nasdaq: OTIC, a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the presentation of previously disclosed clinical results from the successful OTO-413 Phase 12 trial at the upcoming American Academy of Otolaryngology Head and Neck Surgery AAO-HNS Annual Meeting to be held in Los Angeles October 3-6, 2021. The oral presentation will be delivered on October 3, 2021 at 3:15 p.m. PT by Peter G. Volsky, M.D., Assistant Professor of Otology and Neurotology at Eastern Virginia Medical School. Dr. Volsky was an investigator in the trial during his prior clinical service with South Florida ENT Associates. 